An interventional study of Transcranial Magnetic Stimulation, TMS in Chronic Nausea and Vomiting Syndrome, sponsored by David Levinthal. Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by David Levinthal · Not applicable, Interventional, and Basic science
The goal of this study is to determine whether stimulation of the brain-stomach connection can influence stomach activity in healthy adults and in individuals suffering from chronic nausea. The main questions it aims to answer are:
Researchers will use a non-invasive method of brain stimulation called Transcranial Magnetic Stimulation (TMS) and will record stomach responses with skin electrodes on the abdomen.
Participants will:
This study will use cutaneous recordings of stomach activity (electrogastrogram, EGG) and non-invasive brain stimulation with Transcranial Magnetic Stimulation (TMS) to
Some clinical, demographic, and autonomic data (i.e. EKG) will be recorded and used as covariates to investigate any systematic impact on the outcome measures.
793 studies on the registry are indexed under Vomiting; 99 are open to participants now.
This study's planned enrollment of 219 is above the median of 103 across 673 interventional studies indexed under Vomiting.
Browse Vomiting studies →David Levinthal is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects without gastric problems and subjects with Chronic Nausea and Vomiting (CNVS)
Device: Transcranial Magnetic Stimulation, TMS
The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in left and right hand to stimulation of the primary (M1) motor cortex and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are determined. This serves as a reference to determine the best location and stimulation parameters to evoke GMEPs from M1 and pre-motor cortical areas. After identification of the GMEP hot-spot, a stomach filling task (water load test or test meal) is administered and changes in the electrogastrogram (EGG) are monitored. In subsequent study visits, the stomach filling task is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GMEP hotspot.
GMEP location
Location of GMEP hotspot(s) in M1 and/or premotor areas relative to FDI hotspot
Time frame: Baseline session
EGG power change
Change in spectral power of the EGG in the 3 cpm frequency band associated with the gastric filling task (water load or test meal), either followed or not by neuromodulatory rTMS
Time frame: Each study session through study completion, up to 1 year
GMEP amplitude
Amplitude of GMEPs at hotspot
Time frame: Each study session through study completion, up to 1 year
Volume
Volume consumed during the gastric filling task
Time frame: Each study session through study completion, up to 1 year
Nausea severity (only participants suffering from chronic nausea)
Nausea severity rating on an 11-point (0-10) Likert-scale (0=none, 10=worst possible)
Time frame: Each study session through study completion, up to 1 year
Plan to share: Yes — Final analytic de-identified datasets will be deposited in the SPARC data repository.
Time frame: Datasets will be deposited within 2 years of study completion for as long as the SPARC repository is active.
Access criteria: The SPARC repository is publicly accessible.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2030, 54 months after the start.
Of 131 non-industry interventional studies with no phase under Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 54 months is above that.
Counting every sponsor, half of 134 studies reached it within 13 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
David Levinthal